Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 22, No 14S (July 15 Supplement), 2004: 2539
© 2004 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Muta, K. Articles by Harada, M. Search for Related Content PubMed Articles by Muta, K. Articles by Harada, M.

Abstract

Nonmyeloablative allogeneic stem cell transplantation as immunotherapy for pancreatic cancer and other solid tumors

Kyushu University, Fukuoka, Japan

2539

Background: For the treatment of advanced and metastatic disease, conventional anti-tumor therapies such as chemotherapy and radiotherapy have been largely unsuccessful. Particularly in cases of advanced pancreatic cancer, prognosis is extremely poor. Recently, nonmyeloablative allogeneic stem cell transplantation (NST) has been successfully applied for treatment of solid tumors such as renal cell carcinoma. We performed NST in order to establish the role of this immunotherapy in the treatment strategy for Japanese patients with pancreatic cancer and other solid tumors. Methods: Japanese patients under the age of 65 with advanced disease resistant against chemotherapy and/or radiotherapy were enrolled in this pilot study. Fludarabine (Flu) based reduced intensity conditioning was performed prior to the infusion of G-CSF mobilized peripheral blood stem cells obtained from HLA- matched sibling donors. Donor chimerism of both T cells and mononuclear cells (MNC) was determined by PCR-based analysis of polymorphic short tandem repeat markers. In order to investigate the mechanism by which NST elicits an anti-tumor effect, serum levels of TNF were measured by ELISA in four cases of pancreatic cancer. Results: Outcome of patients is given in the table below. Complete T cell chimerism was achieved within 100 days in all cases. Elevation of TNF compared to baseline level was noted in patients #5 and #7, who achieved CR and SD, respectively. Serum levels of TNF were unchanged in patients #6 and #8, who had progressive disease.Conclusions: Successful engraftment and anti-tumor effect of NST were observed. TNF has a possible immunological role during the clinical course of NST.

View larger version (20K): [in this window] [in a new window]

Abstract presentation from the 2004 ASCO Annual Meeting